Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2006

01-07-2006 | Phase I Studies

A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors

Authors: Thierry Delaunoit, Patrick A. Burch, Joel M. Reid, John K. Camoriano, Tomowo Kobayash, Theodore A. Braich, Judith S. Kaur, Joseph Rubin, Charles Erlichman

Published in: Investigational New Drugs | Issue 4/2006

Login to get access
Metadata
Title
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors
Authors
Thierry Delaunoit
Patrick A. Burch
Joel M. Reid
John K. Camoriano
Tomowo Kobayash
Theodore A. Braich
Judith S. Kaur
Joseph Rubin
Charles Erlichman
Publication date
01-07-2006
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/2006
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-006-5392-0

Other articles of this Issue 4/2006

Investigational New Drugs 4/2006 Go to the issue

Phase II Studies

A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)

Phase II Studies

A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma

Preclinical Studies

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

Phase I Studies

Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma

Preclinical Studies

Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin®) in CD1 mice following intravenous and intraperitoneal injection

Preclinical Studies

The Wnt-dependent signaling pathways as target in oncology drug discovery
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits